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To evaluate whether higher omega-6:omega-3 (n-6:n-3) long-chain polyunsaturated 
fatty acid (LCPUFA) ratio in cord plasma is associated with more child Attention 
Deficit and Hyperactivity Disorder (ADHD) symptoms at 4 and 7 years old.  
Study design 
This study was based on a population-based birth cohort in Spain. N-6 arachidonic acid, 
and n-3 eicosapentaenoic and docosahexaenoic acid concentrations were measured in 
cord plasma. At 4 years old, ADHD symptoms were reported by teachers through the 
ADHD-DSM-IV checklist (n=580). At 7 years old, ADHD symptoms were reported by 
parents through the Conners’ Rating Scale-Revised (short form) (n=642). ADHD 
variable was treated as continuous (score) and as dichotomous (symptom diagnostic 
criteria). Child and family general characteristics were prospectively collected through 
questionnaires. We applied pooled zero-inflated negative binomial and logistic 
regressions adjusted for covariates.  
Results 
Higher n-6:n-3 LCPUFA ratio in cord plasma was associated with higher ADHD index 
(Incidence Rate Ratio [IRR]=1.13; 95% Confidence Interval [CI]=1.03, 1.23) at 7 years 
old. The association was not observed at 4 years old (IRR=1.04; 95%CI=0.92, 1.18). No 




High prenatal n-6:n-3 LCPUFA ratio preceded the appearance of subclinical ADHD 
symptoms during mid-childhood. Our findings suggest that maternal diet during 





















Omega-3 (n-3) and omega-6 (n-6) long-chain polyunsaturated fatty acids (LCPUFA) are 
among the main components of cell membranes (1). The main source of these LCPUFA 
in humans is diet (2), which is estimated to contain a n-6:n-3 ratio of 15-20:1 in western 
countries (3). A balanced intake of both series of omega is particularly important, as n-3 
and n-6 compete for incorporation into cell membranes (4) and have opposing 
physiological functions. N-6 promotes systemic pro-inflammatory states, while n-3 
promotes anti-inflammatory states (3).  
N-3 and n-6 LCPUFA comprise approximately 15 to 30% of the brain's dry weight (5). 
Three of these LCPUFA play a crucial role in the function and architecture of the 
central nervous system  (6–8), particularly during the later stages of gestation and early 
postnatal life (9): the n-3 docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids, 
and the n-6 arachidonic acid (AA). During these periods, the main source of n-3 and n-6 
LCPUFA are through placental transfer of these substances and breastfeeding (9). An 
inadequate maternal nutritional pattern during this period could be related to child 
Attention Deficit and Hyperactivity Disorder (ADHD), a neurodevelopmental disorder 
that is estimated to affect 5.3% of the children globally (10). Children with ADHD 
symptoms have higher n-6:n-3 ratio compared to children without symptoms which 
could be due to dietary patterns, altered gut microbiota or abnormal LCPUFA 
metabolism (7,11–13). Whether high prenatal n-6:n-3 LCPUFA ratio precedes the 
appearance of ADHD symptoms during childhood, which may suggest a role in the 
development of the symptoms, remains unknown.  
Following developmental origins of health and disease (DOHAD) theory (14), our study 
aimed to analyze the association between n-6(AA):n-3(DHA+EPA) LCPUFA ratio 
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concentration in cord plasma, a proxy of fetal LCPUFA availability during late 
gestation (15), and child ADHD symptoms at 4 and 7 years of age. We hypothesized 
that higher n-6:n-3 ratios were associated with more child ADHD symptoms. 
Methods 
Subjects 
This study was based on a Spanish population-based birth cohort, including four 
Spanish regions: Asturias (n=494), Gipuzkoa (Basque Country) (n=638), Sabadell 
(Catalonia) (n=657), and Valencia (n=855). Between November 2003 and January 
2008, pregnant women who visited the public health centers for their first trimester 
ultrasound examination were invited to participate in the project if they fulfilled the 
following inclusion criteria: age 16 years or older, singleton pregnancy, no use of 
assisted reproductive techniques, intention to deliver at the reference hospital, and 
ability to speak and understand Spanish or a local language. A baseline survey was 
performed at enrollment (approximately 12 weeks of pregnancy), and follow-up surveys 
were performed at 20 and 32 weeks of pregnancy, at birth, and when children were 6 
months, and 1, 2, 4 or 5, and 7 years old. LCPUFA were assayed in 953 cord plasma 
samples based on availability. In total, 580 and 642 children in the 4-year-old and 7-
year-old assessment periods, respectively, had data both on LCPUFA and ADHD and 
were included in the present analyses (Figure 1). All parents signed the informed 
consent form approved by the Clinical Research Ethical Committees of the Asturias, 
Donostia (Gipuzkoa), La Fe (Valencia) Hospitals, and the Medical Assistance 




Whole blood samples were collected by using venipuncture of cord vessels before the 
placenta was delivered. Samples were processed, separated into aliquots of 1 mL, and 
then frozen to −80°C until the time of analysis. In a subsample of cord plasma, 
LCPUFA methyl esters were prepared and extracted following the method developed 
and validated by Moltó-Puigmartí et al. (16). LCPUFA were then separated and 
quantified by using fast-gas chromatography with flame ionization detection. The 
measurement of LCPUFA in plasma reflects the dietary availability of these 
components during the last 2-3 days (17). The relative amount of each LCPUFA 
quantified was expressed as the percentage of the total FAs. The n-6:n-3 LCPUFA ratio 
was calculated by dividing AA percentage by the sum of the DHA and EPA percentages 
(3,18). Higher ratio reflects higher imbalance between both series of omega. 
ADHD characterization 
At 4 year of age, teachers reported the ADHD symptoms of the participants by using the 
ADHD-DSM-IV (Diagnostic Manual of Mental Disorders, 4
th
 ed) form list (19), which 
consists of 18 symptom-items categorized under two symptom subscales: the inattention 
subscale (nine symptoms) and the hyperactivity-impulsivity subscale (nine symptoms). 
Each ADHD symptom-item was rated on a four-point scale (0=never or rarely, 
1=sometimes, 2=often, or 3=very often), so the total ADHD symptoms score ranges 
between 0 and 54, and the inattention and the hyperactivity-impulsivity subscales scores 
range from 0 to 27. We recorded the options 0 and 1 as 0 (symptom absent), and ratings 
of 2 and 3 as 1 (symptom present) (20). We generated a dichotomous variable of ADHD 
symptom diagnostic criteria, using 6 symptoms as cut off point. The ADHD-DSM-IV 
form list showed good internal consistency, with Cronbach Alpha coefficients of 0.90 




At 7 years of age, parents reported the ADHD symptoms by using the Revised Conners’ 
Parent Rating Scale Short Form (CPRS-R:S) (21), which consists of 27 items 
summarized on four subscales: ADHD index (twelve items), oppositional (six items), 
cognitive problems/inattention (six items), and hyperactivity (six items). Each item was 
rated on a four-point scale (0=never or rarely, 1=sometimes, 2=often, or 3=very often). 
Therefore, the ADHD index score ranges between 0 and 36, and the other subscales 
range between 0 and 18. We generated a dichotomous variable of ADHD symptom 
diagnostic criteria, using T score of 66 as cut off point (21). The CPRS-R:S showed 
good internal consistency, with Cronbach Alpha coefficients of 0.91 for the ADHD 
index, 0.85 for the oppositional subscale, 0.89 for the cognitive problems/inattention 
subscale, and 0.82 for the hyperactivity subscale. 
Higher scores in ADHD-DSM-IV and CPRS-R:S indicates more ADHD symptoms.  
Covariates 
We used face-to-face questionnaires to collect data on maternal education (primary or 
lower, secondary and university), occupation, maternal age, and parity during the first 
trimester of pregnancy (zero, one and two or more). Data on maternal tobacco use was 
collected at the third trimester of pregnancy. Child’s date of birth, gender, and birth 
weight were obtained from clinical records. Gestational age at delivery was based on the 
self-reported date of last menstrual period and it was corrected using crown-rump length 
measurement from an early ultrasound. We collected data on breastfeeding at 6 months 
and 1.5 years through a questionnaire. We calculated child’s age based on birth date and 
ADHD assessment date. We used the Food Frequency Questionnaire (FFQ) (22) to 
collect information on maternal diet between weeks 12 and 32 of pregnancy and on 
child diet at 4 years old. We calculated the relative Mediterranean Diet Score, an 
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indicator of adherence to the Mediterranean diet, for the mothers based on the 
consumption of vegetables, fruits and nuts, cereals, legumes, fish, olive oil, meat, and 
dairy products (23). Maternal mental health was measured through the Global Severity 
Index of the Symptom Checklist-90-R (SCL-90-R) (24) and their verbal IQ proxy was 
tested through the Similarities subtest of the Wechsler Adult Intelligence, 3
rd
 edition 
(WAIS-III) (25) when children were 4 years old.  
Statistical analyses 
We evaluated differences in n-6:n-3 ratio and ADHD symptom scores by socio-
demographic characteristics using Kruskal-Wallis test. The continuous variables of 
child age, maternal mental health and maternal IQ proxy were split in categories for 
these tests. We used the median for splitting child age and tertiles for maternal 
variables. We evaluated sample differences between complete cases and incomplete 
cases and between cohort regions using Fisher’s exact test for categorical variables and 
Kruskal-Wallis test for continuous variables. 
We evaluated crude and adjusted associations between n-6:n-3 ratio and ADHD 
symptoms at 4 (n=580), and at 7 years old (n=642). To avoid underestimation of the 
outcome due to missing values in scale items, we multiplied the obtained raw score by 
the total number of items on the scale, divided by the total number of items that had 
responses, and then rounded to the nearest whole number (21). As ADHD symptoms 
occur as a continuum in the general population (26), this variable was primarily treated 
as continuous (score) and as dichotomous (symptom diagnostic criteria) to follow a 
more clinical approach. For the continuous outcomes, we applied zero-inflated negative 
binomial regression models, previously shown to improve the statistical modelling of 
ADHD studies (27). This method combines and simultaneously estimates two separate 
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regression models. The excess of zeros is modelled under a logistic distribution, and the 
count data with the standard negative binomial distribution. For the dichotomous 
outcome, we performed logistic regression models. We adjusted the models for 
maternal education, sex, age, and region. The confounders were selected a priori based 
on previous studies (28,29) and after building a Directed Acyclic Graph (DAG) (Figure 
2; online). We also tested the heterogeneity of the associations between regions using 
the I
2 
statistic, as well as the interaction terms between n-6:n-3 ratio and sex in the 
association with ADHD symptoms.  
We applied inverse probability weighting (IPW) to control the potential selection bias 
induced by restricting the analysis to complete cases (30). Only individuals with 
observed data were analyzed but we used weights to rebalance the set of complete cases 
so that it is representative of the whole sample. We predicted the probability of being a 
complete case using logistic regression to generate the inverse probability weights 
(Tables 1 and 2; online). Breastfeeding, maternal social class, prematurity and smoking 
during pregnancy contained missing values (<2%) that were singly imputed as the 
variable median value. 
We performed some sensitivity analyses. First, we ran the model without including 
IPW. Second, we additionally adjusted the models for maternal mental health and IQ 
proxy, maternal and child fish intake (together and separately), and maternal adherence 
to Mediterranean diet. Although these variables were not considered confounders and 
the sample size was reduced up to 16%, we tested whether the inclusion of these 
variables in the models modified the effect estimates of the main analyses. Third, we 
repeated the models for each specific LCPUFA (AA, EPA and DHA).  
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We used R (3.0.2; R Foundation for Statistical Computing) and Stata 12.1 (Stata 
Corporation, College Station, Texas) to perform the statistical analyses. 
Results 
Participants had a mean age of 4.85 (SD=0.72) and 7.35 (SD=0.63) years old at each of 
the assessment periods. The sample was equally distributed by sex (48% of the 
participants were females). The mean of maternal age at delivery was 32 years old 
(SD=4), 45% of the mothers were manual workers and 40% had secondary education 
levels. Three percent of the participants were born preterm and the breastfeeding 
duration mean was of 27 weeks (SD=22).  
The concentrations of LCPUFA in cord plasma and the ADHD scores at both 
assessment periods are described in Table 3.  
Table 4 presents the median values of the n-6:n-3 LCPUFA ratio concentrations and the 
ADHD scores according to socio-demographic characteristics. The ADHD symptom 
reports were associated with child’s age and sex, maternal education, mental health and 
IQ. The n-6:n-3 ratio was associated with child’s age and maternal education. Tables 5 
and 6 (online) show that the main variables were differently distributed across the 
Spanish cohort regions included in this study.  
Table 7 describes weighted crude and adjusted associations between n-6:n-3 ratio and 
ADHD symptoms, treated as dichotomous and continuous variable, at 4 and 7 years old. 
We observed that n-6:n-3 LCPUFA ratio in cord plasma did not predict the risk of 
presenting ADHD symptom diagnostic symptom criteria at 4 years old (OR=1.11; 
95%CI=0.73, 1.71). Similarly, no association was observed with the continuous ADHD 
symptoms score (IRR=1.04; 95%CI=0.92, 1.18), without differences between subscales. 
We did not observe substantial heterogeneity among cohorts (I
2
=5.7%, P=0.365), nor 
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interaction by child sex (P for interaction=0.124). At 7 years old, we did not obtain a 
statistically significant association using the outcome variable as dichotomous 
(OR=1.40; 95%CI=0.98, 2.00), however, we found that the ADHD index increased a 
13% per each n-6:n-3 LCPUFA ratio unit (IRR=1.13; 95%CI=1.03, 1.23). The 
subscales that showed statistically significant associations were the cognitive 
problems/inattention (IRR=1.12; 95%CI=1.01, 1.25) and the hyperactivity subscales 
(IRR=1.13; 95%CI=1.02, 1.25). There was a significant heterogeneity between cohort 
regions in some subscale outcomes, specifically in the oppositional and the 
hyperactivity subscales, causing almost 60% of the total variability in the estimates. In 
those cases, the associations were strong in Asturias, while they were weak in the other 
regions (data not shown). The interaction term between n-6:n-3 ratio and sex in the 
association with ADHD index was not significant (P for interaction=0.418).  
The results were similar but weaker when IPW was not applied in the models (Table 8; 
online). The inclusion of maternal mental health and IQ proxy scores, maternal and 
child fish intake (together and separately), and maternal Mediterranean diet in the final 
weighted models did not change the results meaningfully (Table 9; online).   
In further analyses using each LCPUFA component separately as exposure in weighted 
and adjusted models, we observed that DHA was negatively associated with ADHD 
symptoms at 7 years old, EPA was positively associated with ADHD symptoms at 4 
years old, and AA was not associated with ADHD symptoms (Table 10; online). 
Discussion 
In this study, we observed an association between n-6:n-3 ratio (AA/EPA+DHA) 
concentration in cord plasma and subclinical ADHD symptom scores during childhood. 
We found that ADHD symptom scores increased about 13% per each n-6:n-3 ratio unit 
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at 7 years old, although this association was not observed at 4 years old. In separated 
association analyses, DHA seemed to present a major role in this association. The 
longitudinal approach of this study allowed us to demonstrate that higher prenatal n-6:n-
3 LCPUFA ratio preceded subclinical ADHD symptoms during childhood. 
The present findings are consistent with previous studies that have linked the prenatal 
and perinatal n-6:n-3 ratio intake or in maternal fluids with early neurodevelopment 
(31–34). N-6:n-3 ratio intake during pregnancy showed negative associations with 
language, psychomotor, cognitive and social development at early ages (31,32). Higher 
ratio measured in maternal serum during pregnancy was related to slower psychomotor 
development at 9 months (33). N-6:n-3 ratio in breast milk and in plasma phospholipids 
at 44 weeks of gestational age was negatively associated with mental and motor 
development in premature infants (34).  
Both series of omega have important physiological functions in the brain, n-3 modulates 
the synthesis, transport and release of neurotransmitters (8), and n-6 is involved in 
signal activation and reception (2). When n-6 ingestion is higher than n-3 LCPUFA, the 
first one replaces the last in the neuron membrane, altering its function and promoting a 
pro-inflammatory state (4). According to our finding, high prenatal n-6:n-3 ratio 
concentration in cord plasma is associated with ADHD symptoms during childhood and 
this association may be driven by low DHA concentrations. The high ratio during 
development could be related to the appearance of ADHD symptoms through early fetal 
programming. The nutrient supply during early stages of life programmes the structure 
and the function of the organs, which has an impact on individual’s health (35). The 
brain is particularly vulnerable to misprogramming due to its long period of 
development (36,37). These alterations could lead to neurodevelopmental disorders, 
such as ADHD, since monoaminergic systems have been found to be affected by 
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LCPUFA status (38). It has been demonstrated in rodents that decreased concentrations 
of DHA during development alter neurobiological pathways, which has long-term 
negative consequences on behaviour (39). A recent study in humans showed an early 
association of LCPUFA-related genotypes with cognitive performance at school age 
after correction for current DHA blood concentrations, demonstrating the programming 
effect of these nutrients on the brain development (40). Nevertheless, the use of 
LCPUFA supplements during pregnancy for preventing behavioral problems is not 
supported by clinical trials (41–44). Interestingly, we also observed a positive 
association between EPA and ADHD symptoms at 4 years old. Although we are not 
aware of any explanation for this unexpected finding, a similar result was reported in a 
German birth cohort study. The authors of this study observed that higher EPA 
concentrations in cord blood serum were associated with more conduct problems at 10 
years old (45).  
In the present study, we assessed ADHD symptoms during two different periods, at 4 
and 7 years old, but we only observed associations with n-6:n-3 ratio in the second 
period. This finding could be explained by the measurement error at early ages, since 
the ADHD symptoms reported could be originated by a delay in neurodevelopment 
within normality (46). Indeed, ADHD symptom phenotype is usually detected at school 
age (10). Furthermore, the different instruments and informants used at 4 and 7 years 
old could also explain the observed differences, since agreement between parents and 
teachers regarding ADHD symptoms is usually relatively poor (47). Our main findings 
remained significant after adjusting the models for key confounders selected by DAG 
models, and for other variables, identified in the literature, that could modify the 
associations as well. Such associations were not explained by maternal mental health, 
IQ proxy, and other LCPUFA-related nutrients obtained from diet during pregnancy, 
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neither by child diet. This is probably explained by the fact that the LCPUFA ratio in 
cord plasma is a valid measurement of the LCPUFA internal concentration and the one 
that the fetus gets at the end of the pregnancy period. Furthermore, the LCPUFA ratio 
associations observed here were partly driven by Asturias, where the fish consumption, 
both in mothers during pregnancy and in children, was higher than in the rest of the 
cohort regions. These differential dietary habits, combined with the relatively low 
prevalence of ADHD symptoms, could explain the heterogeneity detected in the 
associations between cohort regions. 
In this study, prenatal n-6:n-3 ratio did not influence the risk of presenting ADHD 
symptom diagnostic criteria during childhood. However, we found significant 
associations with the continuous score of ADHD symptoms. Despite the relatively low 
and clinically irrelevant effect estimates obtained, these are important at the population 
level. If the whole population is exposed to high n-6:n-3 ratio, the distribution for 
ADHD symptom scores would likely move to the right, and the prevalence of extreme 
values would increase substantially, which may have a negative impact on the 
community’s health costs and productivity (48).  
This study presents some limitations. The measurement of LCPUFA in cord plasma did 
not reflect long-term dietary exposure to these components, as adipose tissue or red 
blood cells. The missing data due to the lack of cord plasma samples and follow up lost 
could have biased the results and led to low external validity. This limitation was 
minimized by applying Inverse Probability Weighting (IPW) in all the analyses. 
Moreover, we measured ADHD symptoms of children indirectly, and the informants 
and instruments were different at each assessment period. This could reduce the 
comparability of results between both age periods, limiting our ability of disentangling 
age from both instrument and informant influence on ADHD symptoms score.  
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This study encompasses several strengths. We used a large sample size from a 
population-based birth cohort in which different Spanish regions were represented, 
which guarantees a relative degree of generalization of the results to the general 
population. The longitudinal design of this study allowed us to discard the reverse 
causation that can affect cross-sectional studies. We collected the key LCPUFA for 
brain development, AA, DHA, and EPA, from cord plasma, instead of using a single 
determination collected from maternal biological samples or intake estimations. The use 
of a dimensional approach for the ADHD variables allowed us to study subtle 
subclinical dysfunction and increase statistical power. Finally, the models were adjusted 
for the main confounders identified in the literature after following DAG models and 
other additional important variables that could influence the tested associations.  
Conclusion 
High prenatal n-6:n-3 ratio was associated with subclinical ADHD symptoms during 
mid-childhood. Our finding suggests that maternal diet during pregnancy may modulate 
the risk to develop long-term ADHD symptoms in the offspring. Future research should 
measure ADHD symptoms using the same rating scales across assessment periods to 
further understand the trajectory patterns of this complex outcome. Longer follow-ups 
are warranted to explore the stability of this long-term association until adolescence 
periods; and randomized trials are needed to explore the potential nutritional sources of 
such LCPUFA ratio to improve nutritional guidelines during pregnancy.  
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Figure 1. Flowchart of the study population 
 
ADHD: Attention Deficit and Hyperactivity Disorder; ADHD-DSM-IV: Diagnostic Manual of Mental 
Disorders, 4
th
 edition; CPRS-R:S: Revised Conners’ Parent Rating Scale Short Form; LCPUFA: long-






























Figure 2. Directed Acyclic Graph 
 
ADHD: Attention Deficit and Hyperactivity Disorder; IQ: Intelligence Quotient; LCPUFA: long-chain 
polyunsaturated fatty acids 
 
Table 1. Socio-demographic characteristics of the study participants
a
 and non-










Child age in years, mean (SD) 4.85 (0.72) 4.94 (0.68) <0.001 
Child sex, % females 48.28 48.57 0.469 
Region, % <0.001 
Asturias 13.79 20.06  
Gipuzkoa 18.45 25.73  
Sabadell 43.79 19.53  
Valencia 23.97 34.69  
Birth weight in grams, mean 
(SD) 
3296.39 (439.10) 3240.50 (494.71) 0.022 
Gestational age in weeks, 
mean (SD)  
39.73 (1.39) 39.54 (1.80) 0.114 
Preterm, % 2.97 5.19 0.015 
Any breastfeeding in weeks, 
mean (SD) 
27.29 (22.32) 23.80 (21.77) <0.001 
Maternal age, mean (SD) 31.74 (3.81) 31.27 (4.51) 0.017 
Maternal occupation, %  <0.001 
I/II managers/technicians 22.97 20.87  
III non-manual 31.26 24.12  
IV/V manual  45.77 55.01  
Maternal education level, % 0.013 
Primary 20.69 26.27  
Secondary 42.24 41.22  
University 37.07 32.51  
Parity, % 0.662 
0 55.96 56.32  
1 36.27 36.96  
2+ 7.77 6.72  
Smoking at week 32 of 
pregnancy (cigarettes/day), 
mean (SD)  
0.77 (2.38) 1.19 (3.21) 0.021 




50.36 (10.37) 49.76 (9.71) 0.472 
SD=Standard Deviation. aNumber of children with cord blood LCPUFA, ADHD-DSM-IV, and potential 
confounders available.
 b
Kruskal-Wallis test for continuous variables and Fisher’s exact test for categorical 
variables. cGlobal Severity Index of the Symptom Checklist-90-R (SCL-90R), T score.  
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Table 2. Socio-demographic characteristics of the study participants
a
 and non-










Child age in years, mean 
(SD) 
7.35 (0.63) 7.66 (0.60) <0.001 
Child sex, % females 48.91 48.36 0.423 
Region, % <0.001 
Asturias 11.37 21.03  
Gipuzkoa 22.12 24.78  
Sabadell 42.37 19.23  
Valencia 24.14 34.97  
Birth weight in grams, 
mean (SD) 
3291.82 (423.34) 3240.21 (501.27) 0.032 
Gestational age in weeks, 
mean (SD)  
39.74 (1.39) 39.53 (1.81) 0.084 
Preterm, % 2.52 5.41 0.001 
Any breastfeeding in weeks, 
mean (SD) 
27.24 (21.73) 23.69 (21.96) <0.001 
Maternal age, mean (SD) 31.63 (3.89) 31.29 (4.52) 0.104 
Maternal occupation, %  <0.001 
I/II managers/technicians 24.49 20.31  
III non-manual 30.58 24.12  
IV/V manual  44.93 55.57  
Maternal education level, 
%   
0.003 
Primary 21.03 26.34  
Secondary 40.65 41.70  
University 38.32 31.96  
Parity, % 0.551 
0 56.01 56.32  
1 37.91 36.44  
2+ 6.08 7.24  
Smoking at week 32 of 
pregnancy (cigarettes/day), 
mean (SD)  
0.73 (2.36) 1.22 (3.24) 0.002 




49.97 (10.04) 49.95 (9.88) 0.858 
SD=Standard Deviation. aNumber of children with cord blood LCPUFA, Conners’ Rating Scale-Revised, 
and potential confounders available. 
b
Kruskal-Wallis test for continuous variables and Fisher’s exact test 
for categorical variables. cGlobal Severity Index of the Symptom Checklist-90-R (SCL-90R), T score.  
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Table 3. Description of the LCPUFA concentrations in cord plasma and the ADHD variables at 4-year-old and 7-year-old assessment periods of 










Cord plasma (n=715) % AA among total fatty acids 0.32 12.74 14.33 15.94 25.02 
% DHA among total fatty 
acids 
1.68 3.89 4.71 5.95 11.42 
% EPA among total fatty 
acids 
0 0.13 0.19 0.30 2.09 
n-6:n-3 ratio
a
 0.07 2.33 2.86 3.47 6.28 
4-year-old period 
(n=580) ADHD symptom score
b
  
0 1 4 10 52 
 Inattention  0 0 2 5 25 





0 3 6 11 36 
 Oppositional 0 1 3 5 18 
 Cognitive 
problems/inattention 
0 1 2 5 18 
 Hyperactivity 0 1 3 6 18 





ADHD-DSM-IV (Diagnostic Manual of Mental Disorders, 4
th
 edition) symptom score based on 18 items (teachers); 
c
Conners’ Rating Scale-
Revised (short form) ADHD index based on 12 items (parents).  
 
Table 3
Table 4. Median n-6:n-3 ratio in cord plasma and ADHD symptom scores at 4- and 7-year-old periods by socio-demographic characteristics 
  

















Child age (4-year-old) 0.844 0.029   
<4.5 2.83  4    
≥4.5 2.90  5    
Child age (7-year-old) <0.001   1.000 
<7.5 3.13   6  
≥7.5 2.71   6  
Child sex  0.269 <0.001  <0.001 
Females 2.93  3  5  
Males 2.83  6  8  
Maternal mental health
d
  0.360 0.458  <0.001 
1
st
 tertile (35.5-44.2) 2.95  4  4.5  
2
nd
 tertile (44.3-52.5) 2.83  5  6  
3
rd
 tertile (52.6-96.6) 2.95  5  9  
Maternal IQ
e
 0.466 0.184  0.046 
1
st
 tertile (0-9.0) 2.95  4  8  
2
nd
 tertile (9.1-11.2) 2.84  5  6  
3
rd
 tertile (11.3-18.6) 2.89  4  6  
Maternal education  <0.001 0.178  0.001 
Primary 3.03  5  8  
Secondary 3.00  5  7  
University 2.66  4  5  
Table 4




ADHD-DSM-IV (Diagnostic Manual of Mental Disorders, 4
th
 edition) 
symptom score (teachers). 
c
Conners’ Rating Scale-Revised (short form) (parents). 
d
Global Severity Index the Symptom Checklist-90-R (SCL-90R), T score. 
e
Similarities 
subtest of the Wechsler Adult Intelligence, 3rd edition (WAIS III), (mean=10, SD=3). 
 














SD=Standard Deviation; AA= arachidonic acid; DHA=docosahexaenoic acid; EPA=eicosapentaenoic acid; ADHD=Attention Deficit and Hyperactivity Disorder; 
IQ=intelligence quotient. 
a
Kruskal-Wallis test for continuous variables and Fisher’s exact test for categorical variables.
 b











Child age in years, mean (SD)  4.77 (0.39) 4.40 (0.21) 4.44 (0.25) 5.99 (0.40) <0.001 
Child sex, % females 43.75 49.53 51.18 44.60 0.507 
% AA among total fatty acids, mean (SD)  13.26 (1.80) 17.58 (2.29) 13.69 (1.76) 13.51 (2.14) <0.001 
% EPA among total fatty acids, mean (SD) 0.30 (0.15) 0.33 (0.27) 0.19 (0.12) 0.22 (0.18) <0.001 
% DHA among total fatty acids, mean (SD)   4.85 (1.18) 6.90 (1.65) 4.42 (1.16) 4.60 (1.39) <0.001 
n-6:n-3 ratio, mean (SD) 2.73 (0.76) 2.58 (0.77) 3.15 (0.81) 3.01 (0.95) <0.001 
ADHD symptom score, mean (SD)
b
  
All 9.90 (9.94) 5.22 (7.04) 6.70 (7.84) 7.63 (9.07) 0.001 
Males 11.93 (10.56) 6.67 (8.47) 8.23 (9.05) 9.22 (9.82) 0.014 
Females 7.29 (8.51) 3.75 (4.86) 5.25 (6.16) 5.66 (7.66) 0.182 
ADHD diagnostic criteria, %
 c
  
All 16.25 4.67 4.72 17.00 0.001 
Males 22.22 7.41 7.26 18.18 0.014 
Females 8.57 1.89 2.31 4.84 0.276 
Maternal mental health, mean (SD)
d
   50.15 (11.42) 50.35 (9.32) 50.29 (10.51) 50.61 (10.05) 0.833 
Maternal IQ, mean (SD)
e
 9.59 (3.09) 9.60 (2.97) 10.62 (2.89) 10.10 (3.11) 0.013 
Maternal education, %  <0.001 
Primary 11.25 13.08 22.05 29.50  
Secondary 40.00 37.38 43.70 44.60  
University 48.75 49.53 34.25 25.90  
Maternal fish intake, mean (SD)
f 83.64 (52.52) 79.94 (34.13) 64.11 (33.67) 65.36 (37.22) <0.001 
Child fish intake, mean (SD)
g 39.96 (20.37) 34.71 (14.49) 36.78 (17.22) 31.09 (16.90) 0.001 
Maternal Mediterranean diet, mean (SD)
h 8.08 (2.36) 9.25 (2.62) 7.84 (2.40) 7.32 (2.35) <0.001 
Table 5; online only
Disorders, 4
th
 edition) symptom score (teachers). cSix or more symptoms. dGlobal Severity Index of the Symptom Checklist-90-R (SCL-90R), T score. eSimilarities subtest of 
the Wechsler Adult Intelligence, 3
rd
 edition (WAIS III), (mean=10, SD=3). 
f
Food Frequency Questionnaire (FFQ), grams per day, between weeks 12 and 32 of pregnancy. 
g
Food Frequency Questionnaire (FFQ), grams per day, at 4 years old. 
h
Relative Mediterranean Diet Score, constructed with FFQ data considering the consumption of 
vegetables, fruits and nuts, cereals, legumes, fish, olive oil, meat, and dairy products.
  
 














SD=Standard Deviation; AA= arachidonic acid; DHA=docosahexaenoic acid; EPA=eicosapentaenoic acid; ADHD=Attention Deficit and Hyperactivity Disorder; 
IQ=intelligence quotient. 
a












Child age in years, mean (SD)  8.24 (0.33) 7.76 (0.13) 6.73 (0.37) 7.64 (0.19) <0.001 
Child sex, % females 42.47 49.30 51.47 47.10 0.547 
% AA among total fatty acids, mean (SD)  13.34 (1.94) 17.67 (2.21) 13.67 (1.87) 13.54 (2.08) <0.001 
% EPA among total fatty acids, mean (SD) 0.29 (0.12) 0.32 (0.27) 0.19 (0.13) 0.23 (0.18) <0.001 
% DHA among total fatty acids, mean (SD)   4.82 (1.18) 6.77 (1.68) 4.44 (1.14) 4.68 (1.44) <0.001 
n-6:n-3 ratio, mean (SD) 2.76 (0.74) 2.65 (0.75) 3.13 (0.81) 2.96 (0.91) <0.001 
ADHD symptom score, mean (SD)
b
  
All 7.40 (6.64) 7.28 (7.46) 7.96 (7.06) 9.43 (7.12) 0.003 
Males 7.95 (6.42) 8.51 (8.68) 9.50 (7.51) 11.47 (7.51) 0.003 
Females 6.65 (6.96) 6.01 (5.74) 6.51 (6.29) 7.14 (5.90) 0.482 
ADHD diagnostic criteria, %
 c
  
All 5.48 9.15 8.82 10.32 0.692 
Males 4.76 11.11 9.09 10.98 0.670 
Females 6.45 7.14 8.57 9.59 0.933 
Maternal mental health, mean (SD)
d
    49.40 (10.77) 49.24 (9.01) 50.33 (10.55) 50.01 (9.37) 0.721 
Maternal IQ, mean (SD)
e 
 9.64 (3.23) 9.85 (2.86) 10.69 (2.94) 10.16 (3.29) 0.019 
Maternal education, %  <0.001 
Primary 13.70 10.56 22.06 32.26  
Secondary 35.62 35.21 44.49 41.29  
University 50.68 54.23 33.46 26.45  
Maternal fish intake, mean (SD)
f
 80.53 (51.17) 78.75 (29.85) 66.61 (40.16) 65.03 (40.43) <0.001 
Child fish intake, mean (SD)
g
 39.54 (20.81) 34.57 (14.62) 37.48 (17.30) 31.68 (17.14) 0.001 
Maternal Mediterranean diet, mean (SD)
h
 7.93 (2.35) 9.24 (2.64) 7.83 (2.33) 7.30 (2.27) <0.001 
Table 6; online only
c 
T score >66. 
 d
Global Severity Index of the Symptom Checklist-90-R (SCL-90R), T score. 
e
Similarities subtest of the Wechsler Adult Intelligence, 3
rd
 edition (WAIS III), 
(mean=10, SD=3).
 f
Food Frequency Questionnaire (FFQ), grams per day, between weeks 12 and 32 of pregnancy. 
g
Food Frequency Questionnaire (FFQ), grams per day, at 4 
years old. 
h




Table 7. Crude and adjusted associations
a








Subscale (range) Estimate 95% CI  Estimate 95% CI 
4-year-old period
d         
ADHD diagnostic criteria (6 or more 
symptoms) 
1.13 0.77 1.64  1.11 0.73 1.71 
0% 
ADHD (0-52) 1.09 0.95 1.25  1.04 0.92 1.18 5.70% 
Inattention (0-27) 1.09 0.96 1.25  1.05 0.93 1.18 0% 
Hyperactivity-impulsivity (0-27) 1.10 0.93 1.30  1.04 0.89 1.22 0% 
         
7-year-old period
e         
ADHD diagnostic criteria (T score >66) 1.52 1.10 2.11  1.40 0.98 2.00 35.20% 
ADHD (0-36) 1.15 1.06 1.25  1.13 1.03 1.23 23.40% 
Oppositional (0-18) 1.04 0.95 1.15  1.04 0.95 1.15 56.50%* 
Cognitive problems/inattention (0-18) 1.16 1.05 1.28  1.12 1.01 1.25 0% 
Hyperactivity (0-18) 1.16 1.04 1.28  1.13 1.02 1.25 59.20%* 
 
ADHD: Attention Deficit and Hyperactivity Disorder; CI: Confidence Interval. 
a
Incidence Rate Ratio estimated by zero-inflated negative binomial regression models for the 
continuous outcomes and Odds Ratio estimated by logistic regression models for the dichotomous outcome. We applied IPW (Inverse Probability Weighting) in all models. 
b
Models were adjusted for maternal education, child sex, child age and region. 
c
Percentage of the total variability in the estimates that is attributable to heterogeneity between 
regions.
 d
ADHD-DSM-IV (Diagnostic Manual of Mental Disorders, 4
th
 edition) symptom score (teachers). 
d






Table 8. Adjusted associations
a
 between n-6:n-3 ratio in cord plasma and ADHD 
symptoms without applying IPW 
Subscale (range) Estimate 95% CI 
4-year-old period
b    
ADHD diagnostic criteria (6 or more 
symptoms) 
1.13 0.78 1.66 
ADHD (0-52) 1.05 0.94 1.17 
Inattention (0-27) 1.04 0.92 1.17 
Hyperactivity-impulsivity (0-27) 1.06 0.93 1.22 
    
7-year-old period
c    
ADHD diagnostic criteria (T score >66) 1.27 0.91 1.76 
ADHD (0-36) 1.09 1.00 1.18 
Oppositional (0-18) 1.02 0.94 1.12 
Cognitive problems/inattention (0-18) 1.09 0.99 1.21 
Hyperactivity (0-18) 1.09 0.99 1.19 
 
ADHD: Attention Deficit and Hyperactivity Disorder; CI: Confidence Interval; IPW: Inverse Probability 
Weighting. 
a
Incidence Rate Ratio estimated by zero-inflated negative binomial regression models for the 
continuous outcomes and Odds Ratio estimated by logistic regression models for the dichotomous 
outcome.
 
Models were adjusted for maternal education, child sex, child age and region. 
b
ADHD-DSM-IV 
(Diagnostic Manual of Mental Disorders, 4
th
 edition) symptom score (teachers). 
c
Conners’ Rating Scale-
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Table 9. Associations
a
 between n-6:n-3 ratio in cord plasma and ADHD symptoms adjusted for additional variables 
Subscale (range) 
Maternal mental 



























f                    
ADHD diagnostic criteria (6 or more 
symptoms) 
1.12 0.71 1.76 
 
1.15 0.74 1.79 
 
1.23 0.80 1.89 
 
1.27 0.81 2.00 
 
1.12 0.72 1.74 
ADHD (0-52) 1.08 0.94 1.24  1.08 0.95 1.23  1.09 0.97 1.23  1.11 0.98 1.27  1.07 0.94 1.21 
Inattention (0-27) 1.12 0.99 1.26  1.08 0.96 1.22  1.06 0.94 1.21  1.09 0.96 1.24  1.07 0.95 1.21 
Hyperactivity-impulsivity (0-27) 1.06 0.89 1.25  1.09 0.92 1.28  1.12 0.96 1.30  1.14 0.98 1.34  1.07 0.91 1.26 
                    
7-year-old period
g                    
ADHD diagnostic criteria (T score 
>66) 
1.14 0.78 1.65 
 
1.40 0.97 2.02 
 
1.37 0.96 1.97 
 
1.35 0.93 1.97 
 
1.42 0.98 2.04 
ADHD (0-36) 1.09 1.00 1.20  1.11 1.02 1.21  1.13 1.03 1.24  1.12 1.02 1.23  1.12 1.02 1.23 
Oppositional (0-18) 1.00 0.91 1.11  1.04 0.95 1.15  1.06 0.96 1.18  1.07 0.96 1.18  1.04 0.95 1.14 
Cognitive problems/inattention (0-18) 1.09 0.98 1.22  1.12 1.01 1.24  1.12 1.01 1.26  1.12 1.01 1.25  1.13 1.02 1.25 
Hyperactivity (0-18) 1.08 0.97 1.20  1.12 1.01 1.24  1.13 1.01 1.26  1.13 1.01 1.26  1.12 1.01 1.24 
 
ADHD: Attention Deficit and Hyperactivity Disorder; CI: Confidence Interval. 
a
Incidence Rate Ratio estimated by zero-inflated negative binomial regression models for the 
continuous outcomes and Odds Ratio estimated by logistic regression models for the dichotomous outcome. We applied IPW (Inverse Probability Weighting) in all models. 
Models were also adjusted for maternal education, child sex, child age and region. 
b
Global Severity Index of the Symptom Checklist-90-R (SCL-90R), T score, and 
Similarities subtest of the Wechsler Adult Intelligence, 3
rd
 edition (WAIS III), mean=10, SD=3, at the 4-year-old wave. 
c
Food Frequency Questionnaire (FFQ), grams per day, 
between weeks 12 and 32 of pregnancy. 
d
Food Frequency Questionnaire (FFQ), grams per day, at 4 years old. 
e
Relative Mediterranean Diet Score, constructed with FFQ data 
considering the consumption of vegetables, fruits and nuts, cereals, legumes, fish, olive oil, meat, and dairy products.
  f
ADHD-DSM-IV (Diagnostic Manual of Mental 
Disorders, 4
th
 edition) symptom score (teachers). 
g
Conners’ Rating Scale-Revised (short form) (parents).  
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Table 10. Adjusted associations
a
 between each LCPUFA (AA, DHA, and EPA) in cord plasma and ADHD symptoms  
AA, C20:4n-6   DHA, C22:6n-3 
  EPA, C20:5n-3  
Subscale (range) Estimate 95% CI  Estimate 95% CI  Estimate 95% CI 
4-year-old period
c            
ADHD diagnostic criteria (6 or more 
symptoms) 
0.97 0.81 1.16  0.92 0.68 1.24  5.72 1.92 17.03 
ADHD (0-52) 0.99 0.94 1.04  0.96 0.89 1.04  1.59 1.06 2.38 
Inattention (0-27) 0.98 0.93 1.03  0.94 0.88 1.02  1.25 0.83 1.88 
Hyperactivity-impulsivity (0-27) 1.00 0.94 1.06  0.95 0.86 1.05  1.75 1.04 2.96 
            
7-year-old period
d            
ADHD diagnostic criteria (T score 
>66) 
1.04 0.91 1.20  0.75 0.57 0.99  2.88 0.78 10.66 
ADHD (0-36) 1.02 0.98 1.05  0.93 0.89 0.98  1.31 0.98 1.77 
Oppositional (0-18) 1.01 0.98 1.05  0.99 0.93 1.05  1.37 1.00 1.88 
Cognitive problems/inattention (0-
18) 
1.01 0.96 1.05  0.92 0.87 0.98  1.30 0.89 1.92 
Hyperactivity (0-18) 1.03 0.99 1.08  0.95 0.89 1.01  1.25 0.89 1.75 
 
AA: arachidonic acid; ADHD: Attention Deficit and Hyperactivity Disorder; CI: Confidence Interval; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; IRR: 
Incidence Rate Ratio. 
a
Incidence Rate Ratio estimated by zero-inflated negative binomial regression models for the continuous outcomes and Odds Ratio estimated by logistic 
regression models for the dichotomous outcome. We applied IPW (Inverse Probability Weighting) in all models. Models were adjusted for maternal education, child sex, child 
age and region. 
c
ADHD-DSM-IV (Diagnostic Manual of Mental Disorders, 4
th
 edition) symptom score (teachers). 
d
Conners’ Rating Scale-Revised (short form) (parents).  
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 Pregnant women 
(n=2644) 
LCPUFA in cord 
plasma (n=953) 
LCPUFA missing (n=1553) 
ADHD-DSM-IV              
4-year-old period (n=580) 
CPRS-R:S 7-year-old 
period (n=642) 
ADHD missing (n=373)  ADHD missing (n=311)  
Lost/withdrew/miscarriages 
(n=138) 
Newborns at birth 
(n=2506) 
Figure 1












health and IQ 
(4-year-old 
period)  
Child age and 
diet at 4 years 
old 
Child sex 
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 Item 
No Recommendation  Page 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in 
the title or the abstract 
 Abstract (study 
design) 
(b) Provide in the abstract an informative and balanced 
summary of what was done and what was found 
 Abstract 
Introduction   
Background/rationale 2 Explain the scientific background and rationale for the 
investigation being reported 
 Page 6 
Objectives 3 State specific objectives, including any prespecified 
hypotheses 
 Page 6 (last 
paragraph) 
Methods   
Study design 4 Present key elements of study design early in the paper  Page 7 
Setting 5 Describe the setting, locations, and relevant dates, including 
periods of recruitment, exposure, follow-up, and data 
collection 
 Page 7 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources 
and methods of selection of participants. Describe methods of 
follow-up 
Case-control study—Give the eligibility criteria, and the 
sources and methods of case ascertainment and control 
selection. Give the rationale for the choice of cases and 
controls 
Cross-sectional study—Give the eligibility criteria, and the 
sources and methods of selection of participants 
 Page 7 
(b) Cohort study—For matched studies, give matching criteria 
and number of exposed and unexposed 
Case-control study—For matched studies, give matching 
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Variables 7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, if 
applicable 
 Pages 7-9 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details 
of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than one 
group 
 Pages 7-9 
Bias 9 Describe any efforts to address potential sources of bias  Page 10 
Study size 10 Explain how the study size was arrived at  Page 7, figure 1 
Quantitative variables 11 Explain how quantitative variables were handled in the 
analyses. If applicable, describe which groupings were chosen 
and why 
 Pages 10, 11 
(statistical 
analyses) 
Statistical methods 12 (a) Describe all statistical methods, including those used to 
control for confounding 
 Pages 10, 11 
(statistical 
analyses) 
(b) Describe any methods used to examine subgroups and  Pages 10, 11  




(c) Explain how missing data were addressed  Pages 10, 11 
(statistical 
analyses) 
(d) Cohort study—If applicable, explain how loss to follow-up 
was addressed 
Case-control study—If applicable, explain how matching of 
cases and controls was addressed 
Cross-sectional study—If applicable, describe analytical 
methods taking account of sampling strategy 
 Page 11 (IPW) 
(e) Describe any sensitivity analyses  Page 11 
Results  
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, included 
in the study, completing follow-up, and analysed 
Page 7, figure 1 
(b) Give reasons for non-participation at each stage Page 7, figure 1 
(c) Consider use of a flow diagram Figure 1 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, 
social) and information on exposures and potential confounders 
Pages 7-9 
(b) Indicate number of participants with missing data for each variable of 
interest 
Figure 1 
(c) Cohort study—Summarise follow-up time (eg, average and total 
amount) 
Page 7 
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures 
over time 
Table 3 
Case-control study—Report numbers in each exposure category, or 
summary measures of exposure 
 
Cross-sectional study—Report numbers of outcome events or summary 
measures 
 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make clear 
which confounders were adjusted for and why they were included 
Table 7 
(b) Report category boundaries when continuous variables were 
categorized 
Table 4 
(c) If relevant, consider translating estimates of relative risk into absolute 
risk for a meaningful time period 
 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, 
and sensitivity analyses 
Page 11 
Discussion  
Key results 18 Summarise key results with reference to study objectives Pages 12, 13 
Limitations 19 Discuss limitations of the study, taking into account sources of potential 
bias or imprecision. Discuss both direction and magnitude of any potential 
bias 
Page 14 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 




Generalisability 21 Discuss the generalisability (external validity) of the study results Page 16 
Other information  
Funding 22 Give the source of funding and the role of the funders for the present 




*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and 
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